Bambusa Therapeutics' IPO

Q: When is Bambusa Therapeutics' IPO?

9,375,000 shares at $15 to $17 (amended S-1 of Oct 26, 2026). No day set yet.

Q: When does the lock-up end?

Its prospectus sets a lock-up of 180 days; the day it ends is read from its final prospectus once it lists.

9,375,000 shares at $15 to $17 (amended S-⁠1 of Oct 26, 2026). No day set yet.

Range

$15 to $17

Market cap

$796M

9,375,000

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

Once Bambusa Therapeutics lists, Breakaway scores it against every US stock

Its Quality Score from its second session, ranked against 3,191 stocks
Every insider trade, the day it is filed
The lock-up's end on your calendar, once the prospectus dates it
An alert when its score is first set, and when it turns

Get an alert the day BBTX lists

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

From its amended S-1 on SEC EDGAR, filed Oct 26, 2026.

What does Bambusa Therapeutics do?

“We are a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation ("I&I") and fundamentally improve patient quality of life.”

From its amended S-1, filed Oct 26, 2026

Bambusa Therapeutics' facts, each with its source
Fact	Bambusa Therapeutics
Incorporated	Delaware, 2024From its amended S-1 of Oct 26, 2026
Headquarters	Boston, MassachusettsFrom its amended S-1 of Oct 26, 2026
Employees	30 full-time, as of September 30, 2026From its amended S-1 of Oct 26, 2026
Website	bambusatx.comFrom its amended S-1 of Oct 26, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Bambusa Therapeutics' facts, each with its source
Fact	Bambusa Therapeutics
Shares offered	9,375,000From the amended S-1 filed Oct 26, 2026
Price range	$15 to $17 a shareFrom the amended S-1 filed Oct 26, 2026
Net proceeds the company expects	About $135 millionFrom the amended S-1 filed Oct 26, 2026
Underwriters' option	1,406,250 more sharesFrom the amended S-1 filed Oct 26, 2026
Underwriters	BofA Securities, Evercore ISI, UBS, and CantorFrom the amended S-1 filed Oct 26, 2026, as its cover names them
Exchange	Nasdaq Global Select Market, as BBTX (applied to list)From the amended S-1 filed Oct 26, 2026
Shares outstanding after	49,761,875From the amended S-1 filed Oct 26, 2026
Market cap at the midpoint	$796 millionBreakaway's arithmetic from the prospectus's share count

What the filing says about its money

Bambusa Therapeutics' facts, each with its source
Fact	Bambusa Therapeutics
Revenue	None from product sales yetFrom its amended S-1 of Oct 26, 2026: it has not generated any revenue
Last preferred stock	Series A preferredFrom its amended S-1 of Oct 26, 2026

What risks does Bambusa Therapeutics name first?

“We have a limited operating history, which may make it difficult for you to evaluate our current business and predict our future success and viability.”
“Since our formation, we have incurred, and anticipate that we will continue to incur, significant losses and negative cash flows for the foreseeable future.”
“We face substantial competition, including from other biotechnology and pharmaceutical companies, who may discover, develop, or commercialize therapies before or more successfully than we do.”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Every date of Bambusa Therapeutics' IPO

Bambusa Therapeutics' IPO dates, each with its source
What	Day	Source
Registration filedForm S-1, SEC EDGAR	Oct 9, 2026	Form S-1, SEC EDGAR
Price range setamended S-1, SEC EDGAR	Oct 26, 2026	amended S-1, SEC EDGAR
Lock-upPer its amended S-1; the day comes once it lists	180 days	Per its amended S-1; the day comes once it lists

The other IPOs expected

The other IPOs expected or in registration
Company	Price	Market cap	Expected
OPAYNYSE: OPAY · No day yet	$19 to $21	Not yet	No day yetexchange registration Oct 26
Georgia BankingNasdaq: GBC · No day yet	Direct	Not yet	No day yetexchange registration Oct 21
Aspen NeuroscienceNasdaq: ASPE · No day yet	$15 to $17About $465M	$465Mat the midpoint	No day yetterms set Oct 26
BitariNasdaq: BIAI · No day yet	$7About $302M	$302Mat the midpoint	No day yetterms set Oct 26
LIS TechnologiesNasdaq · No day yet	$5 to $7	Not yet	No day yetterms set Oct 26
Unitrend EntertainmentNasdaq · No day yet	$5	Not yet	No day yetterms set Oct 23

Bambusa Therapeutics IPO questions

When is Bambusa Therapeutics' IPO?

9,375,000 shares at $15 to $17 (amended S-⁠1 of Oct 26, 2026). No day set yet.

What is Bambusa Therapeutics' IPO price?

Bambusa Therapeutics set a range of $15 to $17 a share in its amended S-⁠1 of Oct 26, 2026. The final price is set the evening before it lists.

How many shares is Bambusa Therapeutics selling?

9,375,000 shares, and the underwriters may buy 1,406,250 more, per its amended S-⁠1.

Who are the underwriters?

BofA Securities, Evercore ISI, UBS, and Cantor, as the prospectus's cover names them.

When does the lock-up end?

Its prospectus sets a lock-⁠up of 180 days; the day it ends is read from its final prospectus once it lists.

Does Breakaway rate Bambusa Therapeutics?

Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.

Can Breakaway say where Bambusa Therapeutics' price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Once Bambusa Therapeutics lists, Breakaway scores it against every US stock

Its Quality Score from its second session, ranked against 3,191 stocks
Every insider trade, the day it is filed
The lock-up's end on your calendar, once the prospectus dates it
An alert when its score is first set, and when it turns

Get an alert the day BBTX lists

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed.